McGowan L
Department of Obstetrics and Gynecology, George Washington University, Washington, DC 20037.
Clin Nucl Med. 1994 Aug;19(8):696-8. doi: 10.1097/00003072-199408000-00011.
Women diagnosed with early stage ovarian cancer may be considered for adjuvant therapy. Intraperitoneal chromic phosphate (P-32) is commonly used in these patients with few complications. A woman found to have early stage ovarian cancer was given intraperitoneal P-32 in the presence of a lingering pelvic infection, which is usually not mentioned as a contraindication to its use. Radiation damage to the small bowel and cecum developed as did damage to the ureter and bladder, which then required surgery.
被诊断为早期卵巢癌的女性可能会考虑接受辅助治疗。腹膜内注射磷酸铬（P-32）常用于这些患者，且并发症较少。一名被发现患有早期卵巢癌的女性在存在持续性盆腔感染的情况下接受了腹膜内P-32注射，而盆腔感染通常并未被列为使用该治疗方法的禁忌证。结果出现了小肠和盲肠的放射性损伤，输尿管和膀胱也受到了损伤，随后需要进行手术。
